You just read:

Halozyme Doses First Patient In Phase 3 Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine

News provided by

Halozyme Therapeutics, Inc.

Mar 16, 2016, 08:30 ET